CJC w/ DAC 2mg

KEY BENEFITS

• Supports sustained growth hormone (GH) release through extended GHRH pathway activity in research settings

• Long-acting format allows investigation of prolonged GH signaling compared to short-acting GHRH peptides

• Commonly explored for endocrine regulation and recovery-focused research models

• Frequently used in studies examining long-duration GH axis stimulation

• Injectable format supports controlled and consistent systemic exposure in research protocols

Full Description

CJC-1295 with DAC is a synthetic growth hormone–releasing hormone (GHRH) analog that includes a Drug Affinity Complex (DAC) modification. The DAC component allows the peptide to bind to circulating proteins, which significantly extends its functional presence in the body during research studies.

In laboratory and pre-clinical research, CJC-1295 with DAC is commonly used to stimulate endogenous growth hormone release through the body’s native GHRH receptor pathway, while maintaining prolonged and sustained GH signaling. This extended activity makes it well suited for studies focused on longer-duration endocrine modulation, growth hormone output patterns, and downstream regulatory pathways.

Because it activates physiologic GH release rather than supplying exogenous hormone, CJC-1295 with DAC is frequently selected in controlled research environments focused on growth hormone axis regulation, metabolic signaling, and recovery-related endocrine response over extended timeframes.

Commonly Explored For (Research Use Only)

• Sustained growth hormone signaling and output studies

• Endocrine regulation and hypothalamic–pituitary axis research

• Body composition and metabolic pathway investigations

• Recovery and training-adaptation endocrine models

• Long-duration GH axis activation studies